Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators?
Open accessThe DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index; 13 of the 168 sources its claims cite were checked for support.
Abstract
Despite decades of basic and clinical research, our understanding of how benzodiazepines tend to lose their efficacy over time (tolerance) is at least incomplete. In appears that tolerance develops relatively quickly for the sedative and anticonvulsant actions of benzodiazepines, whereas tolerance to anxiolytic and amnesic effects probably does not develop at all. In light of this evidence, we review the current evidence for the neuroadaptive mechanisms underlying benzodiazepine tolerance, including changes of (i) the receptor (subunit expression and receptor coupling), (ii) intracellular changes stemming from transcriptional and neurotrophic factors, (iii) ionotropic glutamate receptors, (iv) other neurotransmitters (serotonin, dopamine, and acetylcholine systems), and (v) the neurosteroid system. From the large variance in the studies, it appears that either different (simultaneous) tolerance mechanisms occur depending on the benzodiazepine effect, or that the tolerance-inducing mechanism depends on the activated receptor subtypes. Importantly, there is no convincing evidence that tolerance occurs with α subunit subtype-selective compounds acting at the benzodiazepine site.
Overview
CoChat Summary
TL;DR
This review synthesizes evidence on neuroadaptive mechanisms of benzodiazepine tolerance, concluding that tolerance develops relatively quickly for sedative/hypnotic and anticonvulsant effects but probably not for anxiolytic and amnesic effects. It finds no convincing evidence that α subunit subtype-selective compounds acting at the benzodiazepine site produce tolerance comparable to classical benzodiazepines.
Key findings
- Tolerance is effect-specific: it develops rapidly for sedative/hypnotic and anticonvulsant actions, whereas tolerance to anxiolytic and amnesic effects most probably does not develop at all. Anticonvulsant tolerance develops during the first several months in 30–50% of epilepsy patients treated with clobazam or clonazepam.
- Proposed mechanisms include GABA_A receptor uncoupling, altered subunit expression, ionotropic glutamate receptor changes, transcriptional/neurotrophic factors, serotonin/dopamine/acetylcholine systems, and neurosteroids; none sufficiently explains tolerance, and the literature is heterogeneous. α5 subunits comprise 15–20% of diazepam-sensitive GABA_A receptors, and α5 together with α1 subunits has been implicated in tolerance to diazepam’s sedative action.
- Subtype-selective α2/α3 compounds show little tolerance in reviewed studies: no tolerance to acute hypothermic, anxiolytic, or sedative effects of diazepam in mice treated for 28 days with TPA023 (unpublished data), no analgesic tolerance after 9-day L838,417 in rats, and no sedative/anticonvulsant tolerance with chronic zolpidem but not midazolam in mice and rats. TPA023 has 0% α1 intrinsic activity versus 23% for TPA123; TPA123 led to benzodiazepine-like reinforcement and withdrawal, whereas TPA023 did not.
- Clinical anxiolytic tolerance was not observed in a double-blind study of 180 chronically anxious outpatients given diazepam 15–40 mg/day for 6–22 weeks, nor after 8 weeks of alprazolam in panic disorder with continued efficacy.
Methods
- Narrative review of basic and clinical literature; no primary experiments or systematic search/meta-analysis are described.
- It reviews evidence on GABA_A receptor subunit expression and coupling, intracellular/transcriptional and neurotrophic factors, ionotropic glutamate receptors, serotonin/dopamine/acetylcholine systems, neurosteroids, and subtype-selective GABA_A receptor modulators.
- Evidence includes preclinical rodent and nonhuman primate studies and clinical studies in insomnia, epilepsy, panic disorder, generalized anxiety disorder, social phobia, and healthy volunteers.
Limitations
- The authors state that understanding of tolerance remains incomplete; studies show large variance due to different methodologies, species, treatment regimens, and benzodiazepines; classical benzodiazepines are treated as a homogeneous class, which may complicate interpretation; molecular results are often not combined with behavioral tests; clinical in vivo binding or postmortem GABA_A receptor expression studies are lacking; no studies directly investigate GABA_A receptor subunit composition after chronic exposure; preclinical tolerance is often not directly related to dose, dosing interval, plasma levels, or half-life; and many studies have relatively short exposure durations.
- Evident from the text: this is a narrative review without a described systematic search or formal quality appraisal, and some key claims about subtype-selective compounds rely on unpublished data from the authors’ laboratory.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 GABAA receptor trafficking and associated proteins. GABAA receptors are assembled from individual subunits in the endoplasmatic reticulum (ER) where the chaperones BiP and Calnexin assist in quality control. Unassembled GABAA receptor subunits that are to be targeted for ER-associated degradation are ubiquitinated and degraded in the proteasome. The ubiquitin-like protein PLIC can interact with GABAA receptors thereby inhibiting their targeting for proteasomal degradation. Assembled pentameric GABAA receptors exit the ER and bind the guanidine exchange factor brefeldin-A-inhibited GDP/GTP exchange factor 2 (BIG2) in the Golgi. Here they also interact with the palmitoylase transferase GODZ and Gamma-aminobutyric acid receptor-associated protein (GABARAP). GABARAP interacts with the NEM sensitive fusion (NSF) protein, as does the GABAA receptor β subunit, and this association may facilitate transport of the receptor complexes to the cell surface. GABAA receptors are inserted at extrasynaptic sites and can diffuse along the plasma membrane in and out of synaptic domains. At synapses they are stabilized by an interaction with the scaffolding protein Gephyrin. The interaction of the GABAA receptor intracellular loops with the μ2 subunit of the adaptin complex AP2 is important for GABAA receptor internalization. GABAA receptors are delivered by a clathrin-mediated pathway to early endosomes where they can be targeted for degradation in the lysosome or for recycling upon binding of Huntington-associated protein (HAP1). Reprinted by permission from Elsevier, reprinted from [101].](https://figures.cochat.ai/paper-figures/44dde951ad1a4298b3801d9931725bcb/mechanisms-underlying-tolerance-after-long-term-benzodiazepine-use-a-future-for-figure-2.jpg)
![Figure 3 Functional crosstalk between G-protein coupled receptors (GPCRs) (which are present in the serotonin, dopamine, acetylcholine system) and GABAA receptors is facilitated through multiple protein kinases and scaffold proteins. GABAA receptor β and γ2 subunits are phosphorylated (P) by PKA and PKC upon the activation of individual GPCRs for dopamine and serotonin. PKA phosphorylation of GABAA receptor β1 and β3 subunits is dependent upon AKAP150/79, which directly interacts with these receptor subunits. AKAP150/79 also binds inactive PKA composed of regulatory (R) and catalytic (C) subunits. In addition, PKC phosphorylates the receptor β1–3 and γ2 subunits. Upon the activation of the appropriate GPCR, PKC-mediated phosphorylation is facilitated by the direct (but independent) interaction of the receptor for activated C kinase (RACK-1) and the β isoform of PKC with the GABAA receptor β1–3 subunits. RACK-1 facilitates functional regulation of GABAA receptors by controlling the activity of PKC associated with these proteins. The GABAA receptor γ2 subunit is also phosphorylated by Src, and this kinase is capable of binding to receptor β and γ2 subunits. Finally, the functional effects of phosphorylation are diverse and range from inhibitions to enhancements of GABAA receptor activity, dependent upon the receptor subunit composition. Reprinted by permission from Elsevier, reprinted from [95].](https://figures.cochat.ai/paper-figures/5ff87939f822496fafdeb2e73768c0b0/mechanisms-underlying-tolerance-after-long-term-benzodiazepine-use-a-future-for-figure-3.jpg)
Verification
Claims the paper makes
7 Valid · 4 Not valid · 97 Not checked · 61 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, the uncoupling process is an aspecific process as it can be induced by exposure to different classes of GABAA receptor modulators acting at different modulatory sites, such as neurosteroids and barbiturates [82].”
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > 4. Mechanisms Underlying Tolerance > 4.2. GABAA System Hypotheses
What the sources say
- Disputedcites [82] Friedman LK Gibbs TT Farb DH γ-aminobutyric acidA receptor regulation: heterologous uncoupling of modulatory site interactions induced by chronic steroid, barbiturate, benzodiazepine, or GABA treatment in culture Brain Research 1996 707 1 100 109 8866718 sourceExperimental — accuracy not yet measured
The Discussion (Section 4) of Friedman et al. (1996) does state that allosteric uncoupling can be induced by 'a variety of GABAAR modulators of different classes, acting at different sites', which supports the illustrative half of the claim, but it frames this only as raising 'the question of the specificity of uncoupling' and then explicitly rejects the aspecific reading: 'The results are also inconsistent with the chronic treatment drug non-specific model, because different chronic drug treatments produced different patterns of uncoupling,' concluding there are at minimum two distinct ways coupling can be modified and, in the Introduction, that 'there may be multiple modes of uncoupling, and ... multiple mechanisms of uncoupling.' Thus the paper contradicts rather than supports the assertion that uncoupling is an aspecific process; the abstract likewise calls it 'Surprising' that different chronic treatments produce different patterns. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In support, BDNF (and NT-4) was found to acutely reduce postsynaptic GABAA receptor immunoreactivity via activation of TrkB receptors [135–139]”
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > 4. Mechanisms Underlying Tolerance > 4.4. Other Mechanisms
What the sources say
- Not checked yetcites [135] Brunig I Penschuck S Berninger B Benson J Fritschy JM BDNF reduces miniature inhibitory postsynaptic currents by rapid downregulation of GABAA receptor surface expression European Journal of Neuroscience 2001 13 7 1320 1328 11298792 source
- Disputedcites [136] Jovanovic JN Thomas P Kittler JT Smart TG Moss SJ Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABAA receptor phosphorylation, activity, and cell-surface stability Journal of Neuroscience 2004 24 2 522 530 14724252 PMC6729993 sourceExperimental — accuracy not yet measured
In “Biphasic temporal modulation of GABAₐR-β3 phosphorylation by BDNF” (page unavailable), the paper reports that BDNF increased—not reduced—cell-surface GABAₐ receptors within 10 minutes; a TrkB inhibitor prevented the increase in surface β3 subunits. These measurements are of cell-surface levels rather than specifically postsynaptic immunoreactivity, and the cited passages provide no NT-4 result. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [137] Tanaka T Saito H Matsuki N Inhibition of GABAA synaptic responses by brain-derived neurotrophic factor (BDNF) in rat hippocampus Journal of Neuroscience 1997 17 9 2959 2966 9096132 PMC6573653 sourceExperimental — accuracy not yet measured
The Abstract reports that BDNF reduced GABAA-mediated responses within five minutes, and “Involvement of postsynaptic TrkB activation” links the reduction in IPSCs to a postsynaptic Trk-type receptor (page numbers unavailable). The paper measures synaptic currents and responses to applied GABA, not postsynaptic GABAA receptor immunoreactivity; it also does not report this effect for NT-4. (LLM, conf=0.90)
- Partly supportedcites [138] Cheng Q Yeh HH Brain-derived neurotrophic factor attenuates mouse cerebellar granule cell GABAA receptor-mediated responses via postsynaptic mechanisms Journal of Physiology 2003 548 3 711 721 12640011 PMC2342883 sourceExperimental — accuracy not yet measured
The Results report that acute BDNF exposure reduced GABAA receptor β2/3 immunoreactivity in cultured cerebellar granule cells, and that K252a prevented the reduction. The Discussion links BDNF's effects to TrkB signalling, but says NT-4/5's possible attenuation of GABA responses in these cells awaited experimentation; it does not report an NT-4/5 reduction in receptor immunoreactivity. Page numbers were not provided in the supplied passages. (LLM, conf=0.90)
- Not checked yetcites [139] Henneberger C Jüttner R Rothe T Grantyn R Postsynaptic action of BDNF on GABAergic synaptic transmission in the superficial layers of the mouse superior colliculus Journal of Neurophysiology 2002 88 2 595 603 12163512 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“One study using α subunit point mutation mice implicated a critical role for α 5 subunits together with α 1 subunits in the decreasing sedative efficacy of the classical benzodiazepine diazepam after chronic treatment [27].”
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > 2. Benzodiazepines and the GABAA System > 2.2. Benzodiazepines from a Nonspecific towards a Subunit-Specific Pharmacology
What the sources say
- Supportedcites [27] van Rijnsoever C Täuber M Choulli MK Requirement of α5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice Journal of Neuroscience 2004 24 30 6785 6790 15282283 PMC6729721 source
The Abstract and the section 'Tolerance to the sedative action of diazepam in point-mutated mice' describe the histidine-to-arginine α-subunit point-mutation knock-in mice (α1, α2, α3, α5) chronically treated with diazepam, where α5(H105R) mice failed to display any sedative tolerance while wild-type, α2 and α3 mice did. The Discussion states that 'α1- and α5-GABAA receptors appear to be the specific molecular substrates contributing in a competitive manner to the chronic effects of diazepam on motor activity,' with α5 interaction essential for the behavioral manifestation of tolerance, and the concluding paragraph proposes tolerance depends on two mechanisms orchestrated by α1- and α5-GABAA receptors. This matches the claim's attribution of a critical joint α5/α1 role in the diminished sedative efficacy of diazepam after chronic treatment. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Using self-administration studies, it was shown that efficacy at α 1-containing GABAA subtypes significantly contributed to the reinforcing effects and withdrawal symptoms of benzodiazepines [8, 28, 29].”
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > 2. Benzodiazepines and the GABAA System > 2.2. Benzodiazepines from a Nonspecific towards a Subunit-Specific Pharmacology
What the sources say
- Partly supportedcites [8] Ator NA Atack JR Hargreaves RJ Burns HD Dawson GR Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at α 1 and α 2/3 subtypes Journal of Pharmacology and Experimental Therapeutics 2010 332 1 4 16 19789360 PMC2802472 sourceExperimental — accuracy not yet measured
Our copy does link self-administration findings to an α1 role in reinforcement, but only tentatively and partly in retreat: the Mechanisms section says 'It initially seemed to us (Ator, 2005) that the α1 subtype must play a prominent role in mediating reinforcing effects' based on high zolpidem/zaleplon self-administration rates, yet immediately notes L-838,417 has no α1 efficacy but maintained self-administration, concluding only that 'elimination of α1 efficacy may play a role' while 'reduction of efficacy at α2/α3 subtypes below 35% may be the critical element', and stating 'It is not possible to discriminate which of these factors is primarily responsible for the reinforcing efficacy.' The withdrawal/dependence part is not attributed to α1: the Physiological Dependence section merely records that chronic administration of nonselective and α1-selective full agonists produced dependence signs, and the Implications paragraph leaves open whether reduced dependence potential reflects 'no α1 efficacy and/or reduced α2/α3 efficacy'. So the claim's confident causal attribution to α1 for both reinforcement and withdrawal overstates this source. (LLM, conf=0.75)
- Not checked yetcites [28] Ator NA Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders CNS Spectrums 2005 10 1 31 39 15618945 source
- Not checked yetcites [29] Griffiths RR Sannerud CA Ator NA Brady JV Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal Journal of Pharmacology and Experimental Therapeutics 1992 260 3 1199 1208 1312162 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Also, more recent indications for reduced allosteric coupling were found after chronic treatment using transfected cell lines that express GABAA receptors or in neurons [84–94].”
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > 4. Mechanisms Underlying Tolerance > 4.2. GABAA System Hypotheses
What the sources say
- Not checked yetcites [84] Wong G Lyon T Skolnick P Chronic exposure to benzodiazepine receptor ligands uncouples the γ—aminobutyric acid type A receptor in WSS-1 cells Molecular Pharmacology 1994 46 6 1056 1062 7808424 source
- Not checked yetcites [85] Tietz EI Chiu TH Rosenberg HC Regional GABA/benzodiazepine receptor/chloride channel coupling after acute and chronic benzodiazepine treatment European Journal of Pharmacology 1989 167 1 57 65 2476326 source
- Not checked yetcites [86] Primus RJ Yu J Xu J Allosteric uncoupling after chronic benzodiazepine exposure of recombinant γ-aminobutyric acidA receptors expressed in Sf9 cells: ligand efficacy and subtype selectivity Journal of Pharmacology and Experimental Therapeutics 1996 276 3 882 890 8786565 source
- Not checked yetcites [87] Pericic D Strac DS Jembrek MJ Vlainic J Allosteric uncoupling and up-regulation of benzodiazepine and GABA recognition sites following chronic diazepam treatment of HEK 293 cells stably transfected with α1β2γ2S subunits of GABAA receptors Naunyn-Schmiedeberg’s Archives of Pharmacology 2007 375 3 177 187 17377772 source
- Supportedcites [88] Klein RL Harris RA Regulation of GABAA receptor structure and function by chronic drug treatments in vivo and with stably transfected cells Japanese Journal of Pharmacology 1996 70 1 1 15 8822084 source
The Results from drug treatments (p. 8) report reduced coupling between GABA and benzodiazepine binding sites after treatment of stably transfected PA3 cells, and compare the finding with uncoupling in neurons. The Conclusions from the stably transfected cells (p. 9) likewise state that chronic-treatment effects on allosteric coupling observed in neurons can be observed in stably transfected cells. (LLM, conf=0.94)
- Not checked yetcites [89] Klein RL Mascia MP Harkness PC Hadingham KL Whiting PJ Harris RA Regulation of allosteric coupling and function of stably expressed γ-aminobutyric acid GABAA receptors by chronic treatment with GABAA and benzodiazepine agonists Journal of Pharmacology and Experimental Therapeutics 1995 274 3 1484 1492 7562525 source
- Not checked yetcites [90] Ali NJ Olsen RW Chronic benzodiazepine treatment of cells expressing recombinant GABAA receptors uncouples allosteric binding: studies on possible mechanisms Journal of Neurochemistry 2001 79 5 1100 1108 11739624 source
- Not checked yetcites [91] Itier V Granger P Perrault G Depoortere H Scatton B Avenet P Protracted treatment with diazepam reduces benzodiazepine1 receptor-mediated potentiation of gamma-aminobutyric acid-induced currents in dissociated rat hippocampal neurons Journal of Pharmacology and Experimental Therapeutics 1996 279 3 1092 1099 8968329 source
- Not checked yetcites [92] Heninger C Gallager DW Altered γ-aminobutyric acid/benzodiazepine interaction after chronic diazepam exposure Neuropharmacology 1988 27 10 1073 1076 2853312 source
- Supportedcites [93] Brett RR Pratt JA Changes in benzodiazepine-GABA receptor coupling in an accumbens-habenula circuit after chronic diazepam treatment British Journal of Pharmacology 1995 116 5 2375 2384 8581272 PMC1909033 source
The GABAA receptor discussion reports reduced benzodiazepine–GABA coupling in several rat brain regions after chronic diazepam treatment, including the nucleus accumbens and lateral habenula. This supports the neuronal-circuit part of the cited statement; the paper used brain-section autoradiography, not transfected cell lines. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
96 more claims · 1 with their cited sources checked
Create a free account to see all 169 claims and to verify the 155 references still open.
- It may state two separate claims as one. 53
- Probably not a substantial claim. 23
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This guidance reflects the general lack of evidence for the long-term clinical benefit of BZDs, as well as research demonstrating that the clinical benefits may decrease over time while the risks persist.32–34”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > 3. The Development of Benzodiazepine Tolerance > 3.2. Clinical Studies on Anticonvulsant Tolerance
“Chronic treatment in rodents with the α 1-preferential compound CL218, 572 resulted in loss of picrotoxin-induced seizures [58].”
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > References
“58. File SE Wilks L Effects of acute and chronic treatment on the pro- and anti-convulsant actions of CL 218, 872, PK 8165 and PK 9084, putative ligands for the benzodiazepine receptor Journal of Pharmacy and Pharmacology 1985 37 4 252 256 2860223”
Citations
Cites
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 1×
“Three classes of the ionotropic glutamate receptor occur in het central nervous system: the NMDA receptor (N-methyl-D-aspartate), the AMPA receptor (alpha-amino-3-hydroxy-5-methyl-4isoxazole-4-propionic acid), and the kainate receptor (for a recent review see [113]).”
BackgroundSynchronization of neuronal activity in hippocampus by individual GABAergic interneurons
Cobb, S. R., Buhl, E. H., Halasy, K., Paulsen, O., & Somogyi, P. (1995) · Nature · doi:10.1038/378075a0 · Cited by 1,498 · cited 1×
“Indeed, increasing knowledge on the specific functions of different GABAA receptor subunits has led to a breakthrough of novel and more selective drugs acting at the benzodiazepine site of the GABAA receptor.”
BackgroundThe yin and yang of neurotrophin action
Lu, B., Pang, P. T., & Woo, N. H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1726 · Cited by 1,356 · cited 1×
“Neurotrophic proteins support neuronal survival, synaptic growth, and differentiation throughout the brain via tyrosine kinase receptors (Trk) and, with lower affinity, via p75 receptors (p75NTRs) [134].”
BackgroundStructure and pharmacology of gamma-aminobutyric acidA receptor subtypes.
Sieghart, W. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06840-1 · Cited by 1,301
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“In support, close neuroanatomical connections exist between GABAergic and glutamatergic neurons [108, 109].”
BackgroundWhich GABAA-receptor subtypes really occur in the brain?
McKernan, R. M., & Whiting, P. J. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)80023-3 · Cited by 1,222
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172 · cited 1×
“Both genetic and pharmacological approaches explored the hypothesis that α subunits differentially contribute to the different effects of classical benzodiazepines The genetic approach consisted of point mutations into specific α subunits (α1(H101R), α2(H101R), α3(H126R), and α5(H105R)), turning them functionally inse…”
BackgroundMcKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944 · cited 2×
“Specifically, α1-containing GABAA receptors probably mediate the sedative, amnesic, and anticonvulsant actions of classical benzodiazepines [13, 23].”
BackgroundSubunit Composition, Distribution and Function of GABA-A Receptor Subtypes
Sieghart, W., & Sperk, G. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023393507 · Cited by 914 · cited 2×
“α5 subunits are predominantly expressed in the hippocampus where they comprise 15–20% of the diazepam-sensitive GABAA receptors [16].”
BackgroundNMDA receptor subunits: function and pharmacology
PAOLETTI, P., & NEYTON, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.011 · Cited by 887
Research works printed but not linked: 1
- Ko D Rho JM DeGiorgio CM Sato S Engel JJ Pedley TA Benzodiazpines Epilepsy: A Comprehensive Textbook 1997 Philadelphia, Pa, USA Lippincott-Raven 1475 1489
Cited by
Benzodiazepine use and risk of Alzheimer's disease: case-control study
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B. (2014) · BMJ · doi:10.1136/bmj.g5205 · Cited by 558
Benzodiazepine use and risk of dementia: prospective population based study
Billioti de Gage, S., Begaud, B., Bazin, F., Verdoux, H., Dartigues, J.-F., Peres, K., Kurth, T., & Pariente, A. (2012) · BMJ · doi:10.1136/bmj.e6231 · Cited by 436
Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.
(2018) · Europe PMC (PubMed Central) · Cited by 250
Benzodiazepine dependence and its treatment with low dose flumazenil
Hood, S. D., Norman, A., Hince, D. A., Melichar, J. K., & Hulse, G. K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12023 · Cited by 165
Association between Benzodiazepine Use and Dementia: A Meta-Analysis
Zhong, G., Wang, Y., Zhang, Y., & Zhao, Y. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127836 · Cited by 164
GABA Receptors: Pharmacological Potential and Pitfalls
Jembrek, M., & Vlainic, J. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150914121624 · Cited by 164
“[10] Vinkers CH, Olivier B.”
Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2020) · Epilepsia · doi:10.1111/epi.16725 · Cited by 148
Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
Baandrup, L., Ebdrup, B. H., Rasmussen, J. Ø., Lindschou, J., Gluud, C., & Glenthøj, B. Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011481.pub2 · Cited by 128
Ng, B. J., Le Couteur, D. G., & Hilmer, S. N. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0544-4 · Cited by 118
Pharmacological Treatment of Insomnia.
(2015) · PubMed Central · Cited by 109
Reddy, S. D., & Reddy, D. S. (2015) · Epilepsia · doi:10.1111/epi.12989 · Cited by 117
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus
Burman, R. J., Rosch, R. E., Wilmshurst, J. M., Sen, A., Ramantani, G., Akerman, C. J., & Raimondo, J. V. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00664-3 · Cited by 106
The Role of Benzodiazepines in the Treatment of Epilepsy
Ochoa, J. G., & Kilgo, W. A. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-016-0401-x · Cited by 99
Wu, X. Y., Kuruba, R., & Reddy, D. S. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.247106 · Cited by 93
“Reduced benzodiazepine efficacy in SE can arise from multiple mechanisms including trafficking or internalization of synaptic GABA-A receptors or other dysfunctions in GABAergic synaptic transmission leading to diminished inhibition (∼50%) in neuronal circuits (Goodkin et al., 2003, 2005, 2007, 2008; Naylor et al., 20…”
BackgroundGABAA receptor subtypes and benzodiazepine use, misuse, and abuse
Engin, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1060949 · Cited by 95
Gravielle, M. C. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.030 · Cited by 91
Chen, K., Wu, M. C., Chen, C., Xu, H., Wu, X., & Qiu, X. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.111747 · Cited by 83
Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials
Braat, S., & Kooy, R. F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.028 · Cited by 83
“Overall, current studies suggest that both neurosteroids and subtype-selective benzodiazepine site agonists do not lead to tolerance, making them suitable for long-term use (Reddy and Rogawski, 2012; Vinkers and Olivier, 2012).”
Rundfeldt, C., & Löscher, W. (2013) · CNS Drugs · doi:10.1007/s40263-013-0129-z · Cited by 77
“In fact, tolerance and withdrawal could be two manifestations of the same compensatory mechanism, with withdrawal occurring when the counterbalancing BZD effect is absent [6].”
BackgroundNicholson, M. W., Sweeney, A., Pekle, E., Alam, S., Ali, A. B., Duchen, M. R., & Jovanovic, J. N. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0100-y · Cited by 77
“Endocytosis of GABA A Rs has also been implicated in long-term effects of benzodiazepines, however the signalling mechanisms that regulate this process, and the effects on inhibitory synapse structure and function, remain poorly characterised 11.”
Withdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Piantadosi, S. C., French, B. J., Poe, M. M., Timić, T., Marković, B. D., Pabba, M., Seney, M. L., Oh, H., Orser, B. A., Savić, M. M., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00446 · Cited by 67
“…effects with no down-regulation of the Gabra5 transcript, commonly observed following chronic benzodiazepine administration (Uusi-Oukari and Korpi, 2010), which potentially explains the development of drug tolerance to benzodiazepine-like pan-GABAA receptor modulators (Vinkers and Olivier, 2012).”
BackgroundPerucca, E., White, H. S., & Bialer, M. (2023) · CNS Drugs · doi:10.1007/s40263-023-01025-4 · Cited by 72
Apland, J. P., Aroniadou‐Anderjaska, V., Figueiredo, T. H., Rossetti, F., Miller, S. L., & Braga, M. F. M. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.217299 · Cited by 68
“…brain is then exposed to DZP, which enhances GABAA receptor activity and thereby stops the SE temporarily but may also contribute to more desensitization and downregulation of GABAA receptors (UusiOukari and Korpi, 2010; Vinkers and Olivier, 2012), further impairing GABAergic synaptic transmission.”
BackgroundCheng, T., Wallace, D. M., Ponteri, B. B., & Tuli, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164307 · Cited by 66
“These complex molecular mechanisms of posttranslational modifications of the GABA A receptor resulting from palmitoylation, ubiquitination, and especially phosphorylation, are believed to dictate the role in regulating the recycling of GABA A receptors through different protein kinases and ultimately impact inhibitory…”
Agarwood Essential Oil Displays Sedative-Hypnotic Effects through the GABAergic System
Wang, S., Wang, C., Peng, D., Liu, X., Wu, C., Guo, P., & Wei, J. (2017) · Molecules · doi:10.3390/molecules22122190 · Cited by 58
Kuruba, R., Wu, X. Y., & Reddy, D. S. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.016 · Cited by 58
Aroniadou‐Anderjaska, V., Figueiredo, T. H., Apland, J. P., & Braga, M. F. M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.017 · Cited by 63
Correcting miR92a-vGAT-Mediated GABAergic Dysfunctions Rescues Human Tau-Induced Anxiety in Mice
Li, X., Wang, Z., Tan, L., Wang, Y., Lu, C., Chen, R., Zhang, S., Gao, Y., Liu, Y., Yin, Y., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.010 · Cited by 54
Castellano, D., Shepard, R. D., & Lü, W. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.616298 · Cited by 61
Clonazepam: Indications, Side Effects, and Potential for Nonmedical Use
Dokkedal‐Silva, V., Berro, L. F., Galduróz, J. C. F., Tufik, S. B., & Andersen, M. L. (2019) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000227 · Cited by 62
Regulation of GABAA receptors by prolonged exposure to endogenous and exogenous ligands
Gravielle, M. C. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.05.015 · Cited by 53
Waters, L. J., Manchester, K. R., Maskell, P., Haegeman, C., & Haider, S. M. (2017) · Science & Justice · doi:10.1016/j.scijus.2017.12.004 · Cited by 54
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“32,33 34 Meta-analyses of patients taking BZDs for insomnia demonstrated minor improvements in sleep onset, increased sleep duration, and decreased nighttime awakenings.”
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
“For the sedative and anticonvulsant actions of benzodiazepines, discontinuation should commence before tolerance develops (i.e., fi rst weeks of use) [94].”
BackgroundSelf-citationUnderstanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology
Lim, B., Sproule, B. A., Zahra, Z., Sunderji, N., Kennedy, S. H., & Rizvi, S. J. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000316 · Cited by 50
Drug tolerance: a known unknown in translational neuroscience
Bespalov, A., Müller, R., Relo, A.-L., & Hudzik, T. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.01.008 · Cited by 50
GABAA Receptor α Subunits Differentially Contribute to Diazepam Tolerance after Chronic Treatment
Vinkers, C. H., van Oorschot, R., Nielsen, E. Ø., Cook, J. M., Hansen, H. H., Groenink, L., Olivier, B., & Mirza, N. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043054 · Cited by 47
“, anxiety, hypothermia or hypolocomotion) [3].”
Self-citationFitzgerald, A. C., Wright, B. T., & Heldt, S. A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3457-x · Cited by 53
Goeldner, C., Kishnani, P. S., Skotko, B. G., Casero, J. L., Hipp, J. F., Derks, M., Hernandez, M.-C., Khwaja, O., Lennon-Chrimes, S., Noeldeke, J., et al. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09418-0 · Cited by 48
“Finally, there is no preclinical evidence suggesting that α5 subtype-selective compounds, such as basmisanil, lead to tolerance [41].”
BackgroundWen, Y., Dong, Z., Liu, J., Axerio-Cilies, P., Du, Y., Li, J., Chen, L., Zhang, L., Liu, L., Lu, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01148-y · Cited by 53
Ferreri, M. C., Gutiérrez, M. L., & Gravielle, M. C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.09.038 · Cited by 48
Wood, M., Daniels, V., Provins, L., Wolff, C., Kaminski, R. M., & Gillard, M. (2020) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.261149 · Cited by 44
“These subunits were chosen because they have been suggested tomediatemany of theBZDs’ pharmacological effects (D’Hulst et al., 2009).”
BackgroundInfluentialHuang, C.-P., Lin, Y., Lee, D.-Y., & Hsieh, C. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/6784735 · Cited by 42
Wright, B. T., Gluszek, C. F., & Heldt, S. A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3473-x · Cited by 42
“Past studies have identified plausible neuroadaptive mechanisms underlying BZs tolerance and withdrawal, including alterations in GABAAR subunit messenger RNA (mRNA) expression (Uusi-Oukari and Korpi 2010; Vinkers and Olivier 2012).”
BackgroundResultInfluentialEffect of Rocking Movements on Afternoon Sleep
van Sluijs, R., Rondei, Q. J., Schluep, D., Jaeger, L., Riener, R., Achermann, P., & Wilhelm, E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01446 · Cited by 47
GABA(A) receptor-targeted drug development -New perspectives in perioperative anesthesia
Antkowiak, B., & Rammes, G. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1599356 · Cited by 44
“Besides alterations in GABAA receptor subunit expression, a functional loss of allosteric coupling and perturbed glutamatergic transmission are possibly involved [39,90].”
BackgroundRasmussen, A. F., Poulsen, S. S., Oldenburg, L. I. K., & Vermehren, C. (2021) · Metabolites · doi:10.3390/metabo11040254 · Cited by 39
Photosensitive epilepsy: Robust clinical efficacy of a selective GABA potentiator
Gurrell, R., Gorman, D. N., Whitlock, M., Ogden, A. G., Reynolds, D. S., DiVentura, B. D., Abou-Khalil, B. W., Gelfand, M. A., Pollard, J., Hogan, R. E., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007271 · Cited by 40
Olivier, J. D. A., & Olivier, B. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9705-0_8 · Cited by 41
Self-citationIshibashi, Y., Nishitani, R., Shimura, A., Takeuchi, A., Touko, M., Kato, T., Chiba, S., Ashidate, K., Ishiwata, N., Ichijo, T., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238723 · Cited by 39
Moncrieff, J. (2017) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796017000555 · Cited by 41
“Tolerance to benzodiazepine effects is also recognised, although the precise mechanism is not known (Vinkers & Olivier, 2012).”
BackgroundSleep quality of benzodiazepine users in nursing homes: a comparative study with nonusers
Bourgeois, J., Elseviers, M. M., Bortel, L. V., Petrovic, M., & Vander Stichele, R. H. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2013.03.012 · Cited by 37
Pomara, N., Lee, S. H., Bruno, D., Silber, T., Greenblatt, D. J., Petkova, E., & Sidtis, J. J. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.08.014 · Cited by 37
An Update on Assessment, Therapeutic Management, and Patents on Insomnia
Porwal, A., Yadav, Y. C., Pathak, K., & Yadav, R. (2021) · BioMed Research International · doi:10.1155/2021/6068952 · Cited by 41
“The physician should also be known to the addictive potentials of these drugs as they may result in euphoria, anxiolysis, and stimulation in certain individuals, especially at higher doses [116].”
BackgroundBialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2022) · Epilepsia · doi:10.1111/epi.17376 · Cited by 39
Wu, P.-P., Cao, B.-R., Tian, F.-Y., & Gao, Z.-B. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-023-01138-2 · Cited by 35
Vossen, L. E., Červený, D., Österkrans, M., Thörnqvist, P., Jutfelt, F., Fick, J. B., Brodin, T., & Winberg, S. (2020) · Environmental Science & Technology · doi:10.1021/acs.est.9b06052 · Cited by 38
Reddy, D. S., Zaayman, M., Kuruba, R., & Wu, X. Y. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108571 · Cited by 35
Steel, T. L., Afshar, M., Edwards, S., Jolley, S. E., Timko, C., Clark, B. J., Douglas, I. S., Dzierba, A. L., Gershengorn, H. B., Gilpin, N. W., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202108-1845st · Cited by 38
“In addition, tolerance may render this class of medication ineffective for SAWS in certain patients (102), mediated by alcohol’s interaction with the GABAA/ benzodiazepine receptor complex (103).”
BackgroundNúñez-Figueredo, Y., Ochoa, E., Verdecia-Reyes, Y., Domínguez, C. C., Parra, A. L., Ramírez-Sánchez, J., Delgado, R., Verdecia, M. P., & Andreu, G. L. P. (2013) · Neurological Research · doi:10.1179/1743132813y.0000000216 · Cited by 38
γ2 GABAAR Trafficking and the Consequences of Human Genetic Variation
Lorenz‐Guertin, J. M., Bambino, M. J., & Jacob, T. C. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00265 · Cited by 34
Diazepam Accelerates GABAAR Synaptic Exchange and Alters Intracellular Trafficking
Lorenz‐Guertin, J. M., Bambino, M. J., Das, S., Weintraub, S. T., & Jacob, T. C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00163 · Cited by 32
Development of a 3D-Printed Dosing Platform to Aid in Zolpidem Withdrawal Therapy
Henry, S., Vadder, L. D., Decorte, M., Francia, S., Steenkiste, M. V., Saevels, J., Vanhoorne, V., & Vervaet, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101684 · Cited by 30
The STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman Syndrome
Bird, L. M., Ochoa‐Lubinoff, C., Tan, W., Heimer, G., Melmed, R. D., Rakhit, A., Visootsak, J., During, M. J., Holcroft, C., Burdine, R. D., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011409 · Cited by 29
Foitzick, M. F., Medina, N. B., Iglesias-García, L. C., & Gravielle, M. C. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134801 · Cited by 31
Muglia, P., Hannestad, J. O., Brandt, C., DeBruyn, S., Germani, M., Lacroix, B. D., Majoie, M., Otoul, C., Sciberras, D. G., Steinhoff, B. J., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa183 · Cited by 28
“PSL was designed specifically to bind with low-to-moderate affinity to the benzodiazepine site, displaying a partial agonist profile—such properties can help minimize the potential for tolerance (Serra et al., 1994; Bateson 2002; Rudolph and Knoflach 2011; Vinkers and Olivier 2012).”
BackgroundAre Seniors Dependent on Benzodiazepines? A National Clinical Survey of Substance Use Disorder
Victorri‐Vigneau, C., Laforgue, E., Grall‐Bronnec, M., Guillou-Landréat, M., Rousselet, M., Guerlais, M., FAN‐Network, Feuillet, F., & Jolliet, P. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2025 · Cited by 31
Germán-Ponciano, L. J., Puga-Olguín, A., Rovirosa-Hernández, M. D. J., Caba, M., Meza, E., & Rodríguez‐Landa, J. F. (2020) · Acta Pharmaceutica · doi:10.2478/acph-2020-0022 · Cited by 25
BDZs, Designer BDZs and Z-drugs: Pharmacology and Misuse Insights
Zaami, S., Graziano, S., Tittarelli, R., Beck, R., & Marinelli, E. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210917145636 · Cited by 27
Pharmacological Treatment of Sleep Disorders and Its Relationship with Neuroplasticity
Abad, V. C., & Guilleminault, C. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_365 · Cited by 25
“GABAA has at least 5 glycoprotein subunits, each of which include multiple isoforms (α1-6, β1-3, γ1-3, δ1, ε1, θ1, and ρ1-3) (Vinkers and Olivier 2012).”
Yang, Y., Wang, B., Zhong, Z., Chen, H., Ding, W., & Hoi, M. P. M. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114711 · Cited by 23
Regulation of GABAA Receptors Induced by the Activation of L-Type Voltage-Gated Calcium Channels
Gravielle, M. C. (2021) · Membranes · doi:10.3390/membranes11070486 · Cited by 23
Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study
Brodie, M. J., Chung, S. S., Wade, A. G., Quelen, C., Guiraud-Diawara, A., François, C., Verpillat, P., Shen, V., & Isojärvi, J. I. T. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.04.003 · Cited by 21
Freire, R. C., Amrein, R., Mochcovitch, M. D., Dias, G. P., Machado, S., Versiani, M., Arias-Carrión, O., Carta, M. G., & Nardi, A. E. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000740 · Cited by 20
“There is abundant evidence in the literature that neurosteroids are endogenous allosteric regulators that interact with GABAA receptors to modulate both tonic (extrasynaptic) and phasic (synaptic) inhibition.(45,49,50) In addition, acute or chronic neurosteroid treatment may change GABAA receptor subunit expression, e…”
BackgroundIo, T., Saunders, R., Pesic, M., Petersen, K., & Stoehr, T. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173886 · Cited by 21
Endothelial KCa channels: Novel targets to reduce atherosclerosis-driven vascular dysfunction
Vera, O. D., Wulff, H., & Braun, A. P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1151244 · Cited by 20
Auta, J., Gatta, E., Davis, J. M., Pandey, S. C., & Guidotti, A. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.416 · Cited by 20
Inhibitory and excitatory synaptic neuroadaptations in the diazepam tolerant brain
Lorenz‐Guertin, J. M., Povysheva, N. V., Chapman, C. A., MacDonald, M. L., Fazzari, M., Nigam, A., Nuwer, J. L., Das, S., Brady, M. L., Vajn, K., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106248 · Cited by 22
“In addition to altered GABA A R neurotransmission, excitatory glutamatergic NMDA receptors (NMDARs) that are crucial for synaptic plasticity (Paoletti et al., 2013) are implicated in BZ tolerance mechanisms (Vinkers and Olivier, 2012).”
The impact of chronic benzodiazepine use on cognitive evolution in nursing home residents
Bourgeois, J., Elseviers, M. M., Bortel, L. M. V., Petrović, M., & Stichele, R. V. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2456 · Cited by 21
Saloner, R., Grelotti, D. J., Tyree, G. A., Sundermann, E. E., Ma, Q., Letendre, S. L., Heaton, R. K., & Cherner, M. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002183 · Cited by 19
[Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics].
Vinkers, C. H., Tijdink, J. K., Luykx, J. J., & Vis, R. (2012) · Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank · Cited by 24
Self-citationNavarrete, F., Marín, M., Martínez-Hostyn, L., Rubio, G., & Manzanares, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031430 · Cited by 19
“Abundance and localization of common GABA A receptor subtypes in the brain [16].”
Biggerstaff, A., Kivell, B. M., Smith, J. L., Mian, M. Y., Golani, L. K., Rashid, F., Sharmin, D., Knutson, D. E., Cerne, R., Cook, J. M., et al. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172996 · Cited by 19
Farajdokht, F., Vosoughi, A., Ziaee, M., Araj‐Khodaei, M., Mahmoudi, J., & Sadigh‐Eteghad, S. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05699-7 · Cited by 18
Epidemiologic assessment of benzodiazepine exposure among suicide deaths in Colorado, 2015–2017
Ghosh, T., Bol, K., Butler, M., Gabella, B., Kingcade, A., Kaplan, G., & Myers, L. (2020) · BMC Public Health · doi:10.1186/s12889-020-09250-y · Cited by 17
Kontić, M. Z., Dragić, M., Martinović, J., Mihajlović, K., Brkic, Z., Mitrović, N., & Grković, I. (2023) · Pharmaceuticals · doi:10.3390/ph16030331 · Cited by 17
Bourgeois, J., Elseviers, M. M., Bortel, L. M. V., Petrović, M., & Stichele, R. V. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0203-3 · Cited by 18
Gurrell, R., Iredale, P., Evrard, A., Duveau, V., Ruggiero, C., & Roucard, C. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13927 · Cited by 18
Zou, G., Xia, J., Han, Q., Liu, D., & Xiong, W. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011221 · Cited by 17
Managing benzodiazepine withdrawal during pregnancy: case-based guidelines
Gopalan, P., Glance, J. B., & Azzam, P. N. (2014) · Archives of Women's Mental Health · doi:10.1007/s00737-013-0388-1 · Cited by 16
“Benzodiazepines are anxiolytic medications that act as agonists at the multi-subunit GABAA receptor via mediation of ligand-gated chloride channels, with inhibitory postsynaptic signaling (Vinkers and Olivier 2012).”
BackgroundAcupuncture for senile insomnia: A systematic review of acupuncture point
Lu, G., Chen, F., Guo, C., & Wu, J. T. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105586 · Cited by 16
Effectiveness and Safety of Nitrazepam in Children with Resistant West Syndrome
Zahan, S., Sahu, J. K., Madaan, P., Suthar, R., Pattanaik, S., Saini, A. G., Saini, L. K., Kumar, A., & Sankhyan, N. (2021) · The Indian Journal of Pediatrics · doi:10.1007/s12098-021-03823-4 · Cited by 16
“The effects appear to be linked to the GABA-A receptors [18, 19].”
BackgroundDeconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study
Gidal, B. E., Wechsler, R. T., Sankar, R., Montouris, G., White, H. S., Cloyd, J. C., Kane, M. C., Peng, G., Tworek, D. M., Shen, V., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003253 · Cited by 16
Hypnotic Activity of Capparis spinosa Hydro-alcoholic Extract in Mice
Rakhshandeh, H., Rashidi, R., Vahedi, M. M., Khorrami, M. B., Abbassian, H., & Forouzanfar, F. (2020) · Recent Patents on Food Nutrition & Agriculture · doi:10.2174/2212798411666200727151142 · Cited by 15
mGlu2 mechanism-based interventions to treat alcohol relapse
Vengeliene, V., & Spanagel, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.985954 · Cited by 16
“This initial finding was replicated several times (Zhao et al., 2006; Kufahl et al., 2011; Meinhardt et al., 2021) and extended by showing that stressinduced reinstatement was also suppressed by LY379268 (Zhao et al., 2006; Sidhpura et al., 2010).”
ResultHulkko, A., Murray, G. K., Moilanen, J. S., Haapea, M., Rannikko, I., Jones, P. B., Barnett, J. H., Huhtaniska, S., Isohanni, M. K., Koponen, H., et al. (2017) · European Psychiatry · doi:10.1016/j.eurpsy.2017.06.004 · Cited by 15
“In the longterm use of benzodiazepines the development of tolerance to sedative effects [69] could possibly reduce the cognitive effects.”
BackgroundGutiérrez, M. L., Ferreri, M. C., Farb, D. H., & Gravielle, M. C. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23387 · Cited by 18
“…normal functioning of adult brain; in pathological conditions such as epilepsy, anxiety, schizophrenia, etc. (Gaiarsa et al., 2002; Fritschy and Brunig, 2003; Mohler, 2006); and in pharmacological situations of prolonged administration of benzodiazepines (Bateson, 2002; Vinkers and Olivier, 2012).”
BackgroundMedicine that Causes Memory Loss: Risk of Neurocognitive Disorders
Uddin, M. S., Mamun, A. A., Sarwar, M. S., Chaity, N., Haque, A., Akter, N., & Amran, M. S. (2016) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2016/26317 · Cited by 14
Tanacetum parthenium enhances pentobarbital-induced sleeping behaviors.
Forouzanfar, F., Ghazavi, H., Vahedi, M. M., Tarrah, K., Yavari, Z., Hosseini, A., Aghaee, A., & Rakhshandeh, H. (2020) · PubMed Central · doi:10.22038/ajp.2019.13391 · Cited by 14
“Various adverse-effects, such as dependence and tolerance have been associated with long-term use of benzodiazepines (Vinkers and Olivier, 2012; Ferreri et al., 2015).”
Background
Metadata
- Authors
- Vinkers, C. H., & Olivier, B.
- Affiliations
- Utrecht University (NL)
- Corresponding author
- Vinkers, Christiaan H.
- Venue
- Advances in Pharmacological Sciences
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-19
- ISSN
- 1687-6334 (ISSN-L)
- 1687-6342
- PMC
- PMC3321276
- OpenAlex
- W2041124713
- Cited by
- 195
- References
- 166
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 7 · 2023: 10 · 2022: 17 · 2021: 18 · 2020: 24 · 2019: 16 · 2018: 18 · 2017: 9 · 2016: 16 · 2015: 15 · 2014: 11 · 2013: 8 · 2012: 4
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Advances in Pharmacological Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Keywords
- benzodiazepine tolerance, GABAA receptor, receptor subunit expression, receptor coupling, neural adaptation, neurotrophic factors, transcriptional regulation, ionotropic glutamate receptors, serotonin, dopamine, acetylcholine, neurosteroids, anxiolytic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.